#leopharma | Explore Tumblr posts and blogs

marketresearch98 · 2 years ago

Text

Low Molecular Weight Heparin Industry Survey Report on 2022 Market Opportunities and Threats

The

low molecular weight heparin market is expected to grow from US$ 3,658.27 million in 2021 to US$ 5,733.96 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028.

Low molecular weight heparin (LMWH) is a class of anticoagulants. They are used to prevent blood clots and to treat venous thromboembolism (deep vein thrombosis and pulmonary embolism) and treat myocardial infarction. LMWHs are defined as heparin salts with an average molecular weight of less than 8,000 Da and in which at least 60% of all chains have a molecular weight of less than 8,000 Da. These are obtained by various methods of fractionation or depolymerization of polymeric

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis - https://www.theinsightpartners.com/sample/TIPRE00026174/

The final report will add the analysis of the Impact of Covid-19 in this report Low Molecular Weight Heparin Market.

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Low Molecular Weight Heparin Market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Low Molecular Weight Heparin Market is analyzed and depicted in the report.

Some of the companies competing in the Low Molecular Weight Heparin Market are

Company Profiles

Aspen Holdings

Changzhou Qianhong Bio-Pharma

Leopharma A/S

Teva Pharmaceutical Industries Ltd.

B. Braun Medical, Inc.

Pfizer, Inc.

Sanofi

Dr. Reddy's Laboratories Limited

Abbott

Novartis AG

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used expert techniques for analyzing the Low Molecular Weight Heparin Market; it also offers an examination of the global market. To make the report more potent and easy to understand, it consists of infographics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

MARKET SEGMENTATION

Packaging-Based Insights

The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes. In 2021, the multi-vials segment held a larger share of the market. However, the prefilled syringes segment is expected to register a higher CAGR during 2021–2028.

Application-Based Insights

The global low molecular weight heparin market, based on application, is segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. However, the acute coronary syndrome (ACS) segment is anticipated to register the highest CAGR in the market during the forecast period.

End Use-Based Insights

The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. However, the ambulatory surgical centers segment is anticipated to register the highest CAGR in the market during the forecast period.

The low molecular weight heparin market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio worldwide and to meet the growing demand.

Have a 15-minute-long discussion with the lead analyst and author of the report in a time slot decided by you. You will be briefed about the contents of the report and queries regarding the scope of the document will be addressed as well - https://www.theinsightpartners.com/speak-to-analyst/TIPRE00026174

What questions does the Low Molecular Weight Heparin Market report answer about the regional reach of the industry

· The report claims to split the regional scope of the Low Molecular Weight Heparin Market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

· How do the sales figures look at present How does the sales scenario look for the future

· Considering the present scenario, how much revenue will each region attain by the end of the forecast period

· How much is the market share that each of these regions has accumulated presently

· How much is the growth rate that each topography will depict over the predicted timeline

Immediate delivery of our off-the-shelf reports and prebooking of upcoming studies, through flexible and convenient payment methods - https://www.theinsightpartners.com/buy/TIPRE00026174/

The scope of the Report:

The "Global Low Molecular Weight Heparin Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Low Molecular Weight Heparin market with detailed market segmentation by mechanism of action, application, type and distribution channel. The report provides key statistics on the market status of the leading Low Molecular Weight Heparin market players and offers key trends and opportunities in the market.

Reasons for buy this Report

· Highlights key business priorities to assist companies to realign their business strategies.

· The key findings and recommendations highlight crucial progressive industry trends in the Low Molecular Weight Heparin market, thereby allowing players to develop effective long term strategies.

· Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

· Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

· Enhance the decision-making process by understanding the strategies that underpin commercial interest to components, type, and end-users.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

If you have any queries about this report or if you would like further information, please

Contact Person: Sameer Joshi

E-mail: [email protected]

Phone: +1-646-491-9876

0 notes

pharmaphorumuk · 6 years ago

Text

Pharma takes leading role in NHS 70th anniversary celebrations

The pharmaceutical industry celebrated the 70th anniversary of the NHS by recognising the myriad contributions that the sector has made to the lives of many people.

The Association of the British Pharmaceutical Industry (ABPI) ran a series of announcements headlining the life-changing effects of pharmaceuticals over the years, highlighting the powerful collaboration between the NHS and pharma.

The groundbreaking work carried out by pharma companies has undoubtedly extended and bettered the lives of numerous individuals with acute and chronic conditions by giving the NHS the drugs and equipment with which to save lives.

Cancer medicines have helped to double survival rates over the last 40 years and medicines have helped to decrease heart disease deaths by a staggering 75% since the 1960s. Life expectancy has risen by 10 years since the 60s, too.

As well as developing medicines, the industry makes a significant contribution to the country’s economy. The UK’s life sciences industry is world-leading, contributing £30.4 billion in GDP.

It is also a major employer, giving jobs to 140,000 people directly in 5,500 companies and, for every person employed, the industry supports 2.5 jobs elsewhere in the economy.

Pharma giants including Pfizer UK, MSD, AstraZeneca, LeoPharma and Novartis UK offered their gratitude and praise to the NHS, expressing their pride at supplying life-enhancing medicines to the service and thanking staff for their dedication.

The major pharma players shared their positivity on all that has been achieved since health secretary Aneurin Bevan launched the NHS at Park Hospital in Manchester 70 years ago and reflected on the links that pharma and NHS have developed, as technology has advanced and scientists have made breakthroughs to treat conditions and illnesses that were previously untouchable.

The theme of the message from the ABPI and its member organisations is one of symbiosis and mutual respect, illustrating how – despite the many challenges facing the NHS – the pharma industry is its ally and is ever striving to improve lives.

The post Pharma takes leading role in NHS 70th anniversary celebrations appeared first on Pharmaphorum.

from Pharmaphorum https://pharmaphorum.com/news/pharma-takes-leading-role-in-nhs-70th-anniversary-celebrations/

0 notes